Hairy cell leukemia overview

Revision as of 19:53, 10 January 2019 by Natalie Harpenau (talk | contribs)
Jump to navigation Jump to search

Hairy cell leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hairy cell leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hairy cell leukemia overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hairy cell leukemia overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hairy cell leukemia overview

CDC on Hairy cell leukemia overview

Hairy cell leukemia overview in the news

Blogs on Hairy cell leukemia overview

Directions to Hospitals Treating Hairy cell leukemia

Risk calculators and risk factors for Hairy cell leukemia overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]

Overview

Hairy cell leukemia arises from B cells, that are normally involved in the process of human immunoglobulins production. However, the exact B cell maturation stage involved in the development of hairy cell leukemia is still unclear. The most common gene involved in the pathogenesis of hairy cell leukemia is a BRAF V600E mutation. On microscopic histopathological analysis, characteristic findings of hairy cell leukemia include small cells with "fried egg"-like appearance, well-demarcated thread-like cytoplasmic extensions, and a clear cytoplasm. Hairy cell leukemia is found to approximately comprise 2% of all leukemias in the United States. The incidence of hairy cell leukemia is approximately 3.2 per 1,000,000 individuals in the United States. The incidence of hairy cell leukemia increases with age; the median age at diagnosis is 58 years. Males are more commonly affected with hairy cell leukemia than females. The male to female ratio is approximately 4 to 1. Studies have proposed a number of risk factors for the development of hairy cell leukemia such as certain chemicals exposure, radiation exposure, and sawdust exposure. Symptoms of hairy cell leukemia include fever, night sweats, and weight loss. Physical examination of patients with hairy cell leukemia is usually remarkable for pallor, petechiae, and splenomegaly. Laboratory findings consistent with the diagnosis of hairy cell leukemia include abnormal complete blood count, immunohistochemistry, and flow cytometry. The presence of hairy cells with thread-like cytoplasmic extensions on blood smear is a key diagnostic feature among patients with hairy cell leukemia. There are no curative treatments for hairy cell leukemia. The mainstay of therapy for hairy cell leukemia patients is chemotherapy. Pharmacological agents used for the treatment of hairy cell leukemia patients include cladribine, pentostatin, rituximab, and vemurafenib.

Historical Perspective

The term hairy cell leukemia was first used to describe the malignancy by Dr. R. Schrek and Dr. W. J. Donnelly, in 1966.

Classification

Hairy cell leukemia may be classified into two sub-types which include hairy cell leukemia (classic) and hairy cell leukemia (variant).

Pathogenesis

Hairy cell leukemia arises from B cells, that are normally involved in the process of human immunoglobulins production. However, the exact B cell maturation stage involved in the development of hairy cell leukemia is still unclear. The most common gene involved in the pathogenesis of hairy cell leukemia is BRAF V600E mutation. On microscopic histopathological analysis, characteristic findings of hairy cell leukemia include small cells with "fried egg"-like appearance, well-demarcated thread-like cytoplasmic extensions, and a clear cytoplasm.

Causes

There are no established direct causes for hairy cell leukemia. Common genetic mutations involved in the development of hairy cell leukemia.

Epidemiology and Demographics

Hairy cell leukemia is found to approximately comprise 2% of all leukemias in the United States. The incidence of hairy cell leukemia is approximately 3.2 per 1,000,000 individuals in the United States. The incidence of hairy cell leukemia increases with age; the median age at diagnosis is 58 years. Males are more commonly affected with hairy cell leukemia than females. The male to female ratio is approximately 4 to 1.

Risk Factors

Studies have proposed a number of risk factors for the development of hairy cell leukemia such as certain chemicals exposure, radiation exposure, and sawdust exposure.

Screening

According to the the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine screening for hairy cell leukemia.

Natural History

Most patients with hairy cell leukemia are asymptomatic at the time of diagnosis. If left untreated, most of the patients with hairy cell leukemia will gradually develop anemia, recurrent infections, and recurrent bleeding. The complications of hairy cell leukemia are mainly due to bone marrow failure.

Diagnosis

Staging

There is no established system for the staging of hairy cell leukemia.

History and Symptoms

Symptoms of hairy cell leukemia include fever, night sweats, and weight loss.

Physical Examination

Physical examination of patients with hairy cell leukemia is usually remarkable for pallor, petechiae, and splenomegaly.

Laboratory Findings

Laboratory findings consistent with the diagnosis of hairy cell leukemia include abnormal complete blood count, immunohistochemistry, and flow cytometry. The presence of hairy cells with thread-like cytoplasmic extensions on blood smear is a key diagnostic feature among patients with hairy cell leukemia.

CT Scan

Abdominal CT scan may be helpful in the diagnosis of hairy cell leukemia. The presence of splenomegaly on CT scan is suggestive of hairy cell leukemia.

MRI

MRI of the femur may be helpful in the diagnosis of hairy cell leukemia. Diffuse hyper-intense lesions on T2-weighted MRI image is suggestive of bone marrow infiltration by malignant leukemic cells.

Medical Therapy

There are no curative treatments for hairy cell leukemia. The mainstay of therapy for hairy cell leukemia patients is chemotherapy. Pharmacological agents used for the treatment of hairy cell leukemia patients include cladribine, pentostatin, rituximab, and vemurafenib.

Surgery

The predominant therapy for hairy cell leukemia is chemotherapy. Surgical management, such as splenectomy, may be required in certain cases.

References


Template:WikiDoc Sources